Cybin (HELP) Capital Expenditures (2020 - 2024)

Cybin (HELP) reported Capital Expenditures of $25231.8 for Q1 2024, down 53.65% quarter-over-quarter from $54433.6 in Q1 2023.

Cybin (HELP) Capital Expenditures (2020 - 2024) Analysis & Trends

Cybin has reported Capital Expenditures for 5 years, with the latest figure at $25231.8 in Q1 2024.

For the quarter ending Q1 2024, Capital Expenditures changed N/A year-over-year to $25231.8; the trailing twelve-month figure through Mar 2024 stood at -$21000.7 (changed N/A YoY), and the FY2024 full-year result was $15584.4, changed N/A from the prior year.
Capital Expenditures for Q1 2024 stood at $25231.8, down from $54433.6 in the prior quarter.
The five-year high for Capital Expenditures was $80965.3 in Q1 2022, with the low at -$100666.1 in Q3 2022.
Historically, Capital Expenditures has averaged -$10166.2 across 5 years, with a median of -$16682.6 in 2021.
Annual changes were most pronounced in 2021 — Capital Expenditures jumped 74.72% — and 2022, when it slumped 503.42%.
Cybin's Capital Expenditures stood at -$69034.9 in 2020, then soared by 74.72% to -$17453.4 in 2021, then sank by 476.77% to -$100666.1 in 2022, then soared by 154.07% to $54433.6 in 2023, then slumped by 53.65% to $25231.8 in 2024.
The last three Capital Expenditures figures came in at $25231.8 (Q1 2024), $54433.6 (Q1 2023), and -$100666.1 (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	133.40 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	-63,220.27
10	Cybin	75.42 Mn	75.42 Mn	-	-

Download Data